糖尿病性神経障害の世界市場 - 市場規模、シェア、成長分析：障害別、流通チャネル別、薬剤クラス別、業界予測（2022年～2028年）

世界の糖尿病性神経障害の市場規模は、2021年に36億2,638万米ドルとなり、予測期間（2023年～2030年）に6.9%のCAGRで成長し、2022年の38億7,660万米ドルから2030年までに70億6,725万米ドルに達すると予測されています。

当レポートでは、世界の糖尿病性神経障害市場について調査分析し、市場力学と見通し、セグメント別の分析、企業プロファイルなどの情報を提供しています。

目次

エグゼクティブサマリー

市場概要

親市場分析

市場概要

市場規模

• 市場力学
• 促進要因
• 機会
• 抑制要因
• 課題
• SWOT分析

主要な市場洞察

• 技術分析
• 価格分析
• サプライチェーン分析
• バリューチェーン分析
• 市場のエコシステム
• IP分析
• 貿易分析
• スタートアップ分析
• 原材料分析
• イノベーションマトリックス
• パイプライン製品分析
• マクロ経済指標

新型コロナウイルスの影響

• イントロダクション
• 経済への影響 - シナリオ評価
• 市場規模の修正
• 主要セグメントに対する新型コロナウイルスの影響
• 新型コロナウイルス戦略：企業別

市場力学と見通し

• 市場力学
• 促進要因
• 機会
• 抑制要因
• 課題
• 規制状況
• SWOT分析
• ポーターのファイブフォース分析
• 将来の混乱に関する特別な洞察
• 政治的影響
• 経済的影響
• 社会的影響
• 技術的影響
• 環境的影響
• 法的影響

世界の糖尿病性神経障害市場：障害別

• 市場セグメント
• 末梢神経障害
• 自律神経障害
• 近位神経障害
• 局所神経障害

世界の糖尿病性神経障害市場：流通チャネル別

• 市場セグメント
• 病院
• 診療所
• 小売薬局
• オンライン薬局

市場規模：地域別

• 北米
• 米国
• カナダ
• 欧州
• ドイツ
• スペイン
• フランス
• 英国
• その他の欧州
• アジア太平洋
• 中国
• インド
• 日本
• 韓国
• その他のアジア太平洋
• ラテンアメリカ
• ブラジル
• その他のラテンアメリカ
• 中東・アフリカ
• GCC諸国
• 南アフリカ
• その他の中東・アフリカ

主要企業プロファイル

• 競合情勢
• Johnson & Johnson（米国）
• Boehringer Ingelheim GmbH（ドイツ）
• NeuroMetrix, Inc（米国）
• Eli Lilly and Company（米国）
• GlaxoSmithKline plc（英国）
• Lupin Limited（インド）
• Pfizer Inc（米国）
• Astellas Pharma Inc（日本）
• Glenmark Pharmaceuticals Ltd（インド）
• Arbor Pharmaceuticals, LLC（米国）
• Depomed, Inc（米国）

Global Diabetic Neuropathy Market size was valued at USD 3626.38 million in 2021 and is poised to grow from USD 3876.6 million in 2022 to USD 7067.25 million by 2030, growing at a CAGR of 6.9% in the forecast period (2023-2030).

Diabetic neuropathy is a disorder that affects the nerves and is linked to hyperglycemia. People who have had diabetes for a long time are more prone to have nerve damage throughout their bodies, even when the signs of diabetic neuropathies could not be identified at an early stage. In spite of the fact that diabetic neuropathy cannot be treated, it can be managed or prevented with the aid of a number of therapeutic techniques. Regulating bodies are required to approve more products and therapy techniques that are connected to the condition due to its intricacy. The high prevalence of diabetic neuropathy, which mostly affects diabetic people, will create several expansion opportunities for the companies operating in this industry.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Diabetic Neuropathy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report

The Global Diabetic Neuropathy Market segmentation is based on Disorder, Distribution Channel, and Region. Based on disorder the Diabetic Neuropathy Market is segmented into peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. Based on distribution channels the Diabetic Neuropathy Market is segmented into hospitals, clinics, retail pharmacies, and online pharmacies. Based on region the global Diabetic Neuropathy market is segmented into North America, Europe, Asia-Pacific, Latin America, and MEA.

Driver

An increase in diabetic neuropathy demand due to an increase in diabetes prevalence.

The global demand for diabetic neuropathy will increase more slowly during the projection period due to the increased prevalence of diabetes. Furthermore, it's believed that some of the variables influencing the market's rise include obesity, coronary heart disease, diabetic neuropathy, and other sugar-related problems. Rising urbanisation, which encourages sedentary lifestyles like carbohydrate eating and low physical exercise, also has an impact on the market's expansion.

Expanding R&D efforts by major players to support the diabetic neuropathy market globally.

An rise in the older population and carbohydrate consumption are contributing to an increase in diabetes incidence. As the number of people with diabetes increases worldwide, there is an increasing need for therapies for diabetic neuropathy. The increased government spending to improve health services is also contributing to the market's expansion. Due to the rapid advancement of science and the rising expenditures made by the key industry participants, it is projected that the diabetic neuropathy market would expand in the near future.

Restraint

Expensive prescription drugs and alternative therapies restrain market expansion.

Among the obstacles to market expansion include the rising cost of diabetic neuropathy treatments, the widening selection of complementary therapies, and other factors. The availability of alternative therapies, such as radiotherapy and physical therapy, which are regarded as more comfortable and may offer patients satisfactory clinical outcomes, is one reason restricting the market's development. The strict regulations, product recalls, delays in Food and Drug Administration certifications, and other similar issues may further impede the growth of this industry.

Market Trends

In the upcoming year, high-tech products for better diabetic neuropathy treatment will be produced. Businesses are putting their efforts into developing talc, transdermal patches, and mouthwash, among other things. To address issues with surgical medicines, manufacturers have devised cutting-edge medication delivery technologies, such as syringe-free injection equipment. As a result, NFIT has generated a lot of interest in the disease's therapy, which is aiding the market's growth. Due to the growing need for innovative medication delivery techniques such oral, transdermal, parenteral, and inhalation, the market is growing.

Table of Contents

Executive Summary

Market overview

• Exhibit: Executive Summary - Chart on Market Overview
• Exhibit: Executive Summary - Data Table on Market Overview
• Exhibit: Executive Summary - Chart on Global Global Diabetic Neuropathy Market Characteristics
• Exhibit: Executive Summary - Chart on Market by Geography
• Exhibit: Executive Summary - Chart on Market Segmentation
• Exhibit: Executive Summary - Chart on Incremental Growth
• Exhibit: Executive Summary - Data Table on Incremental Growth
• Exhibit: Executive Summary - Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

• Market Dynamics
• Exhibit: Impact analysis of DROC, 2021
• Drivers
• Opportunities
• Restraints
• Challenges
• SWOT Analysis

KEY MARKET INSIGHTS

• Technology Analysis
• (Exhibit: Data Table: Name of technology and details)
• Pricing Analysis
• (Exhibit: Data Table: Name of technology and pricing details)
• Supply Chain Analysis
• (Exhibit: Detailed Supply Chain Presentation)
• Value Chain Analysis
• (Exhibit: Detailed Value Chain Presentation)
• Ecosystem Of the Market
• Exhibit: Parent Market Ecosystem Market Analysis
• Exhibit: Market Characteristics of Parent Market
• IP Analysis
• (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
• Trade Analysis
• (Exhibit: Data Table: Import and Export data details)
• Startup Analysis
• (Exhibit: Data Table: Emerging startups details)
• Raw Material Analysis
• (Exhibit: Data Table: Mapping of key raw materials)
• Innovation Matrix
• (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
• Pipeline product Analysis
• (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
• Macroeconomic Indicators

COVID IMPACT

• Introduction
• Impact On Economy-scenario Assessment
• Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
• Revised Market Size
• Exhibit: Data Table on Global Global Diabetic Neuropathy Market size and forecast 2021-2027 ($ million)
• Impact Of COVID On Key Segments
• Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
• COVID Strategies By Company
• Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

• Market Dynamics
• Exhibit: Impact analysis of DROC, 2021
• Drivers
• Opportunities
• Restraints
• Challenges
• Regulatory Landscape
• Exhibit: Data Table on regulation from different region
• SWOT Analysis
• Porters Analysis
• Competitive rivalry
• Exhibit: Competitive rivalry Impact of key factors, 2021
• Threat of substitute products
• Exhibit: Threat of Substitute Products Impact of key factors, 2021
• Bargaining power of buyers
• Exhibit: buyers bargaining power Impact of key factors, 2021
• Threat of new entrants
• Exhibit: Threat of new entrants Impact of key factors, 2021
• Bargaining power of suppliers
• Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
• Skyquest special insights on future disruptions
• Political Impact
• Economic impact
• Social Impact
• Technical Impact
• Environmental Impact
• Legal Impact
• Global Global Diabetic Neuropathy Market by Disorder
• Market segments
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Data table on Market share 2021-2027 (%)
• Peripheral Neuropathy
• Market Estimates & Forecast, 2020-2027
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Autonomic Neuropathy
• Market Estimates & Forecast, 2020-2027
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Proximal Neuropathy
• Market Estimates & Forecast, 2020-2027
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Focal Neuropathy
• Market Estimates & Forecast, 2020-2027
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Global Global Diabetic Neuropathy Market by Distribution channel
• Market segments
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Data table on Market share 2021-2027 (%)
• Hospitals
• Market Estimates & Forecast, 2020-2027
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Clinics
• Market Estimates & Forecast, 2020-2027
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Retail Pharmacy
• Market Estimates & Forecast, 2020-2027
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Online Pharmacy
• Market Estimates & Forecast, 2020-2027
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)

Market Size by Region

• Chart on Market share by geography 2021-2027 (%)
• Data Table on Market share by geography 2021-2027(%)
• North America
• Chart on Market share by country 2021-2027 (%)
• Data Table on Market share by country 2021-2027(%)
• USA
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Canada
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Europe
• Chart on Market share by country 2021-2027 (%)
• Data Table on Market share by country 2021-2027(%)
• Germany
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Spain
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• France
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• UK
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Rest of Europe
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Asia Pacific
• Chart on Market share by country 2021-2027 (%)
• Data Table on Market share by country 2021-2027(%)
• China
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• India
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Japan
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• South Korea
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Rest of Asia Pacific
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Latin America
• Chart on Market share by country 2021-2027 (%)
• Data Table on Market share by country 2021-2027(%)
• Brazil
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Rest of South America
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Middle East & Africa (MEA)
• Chart on Market share by country 2021-2027 (%)
• Data Table on Market share by country 2021-2027(%)
• GCC Countries
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• South Africa
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Rest of MEA
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

• Competitive Landscape
• Total number of companies covered
• Exhibit: companies covered in the report, 2021
• Top companies market positioning
• Exhibit: company positioning matrix, 2021
• Top companies market Share
• Exhibit: Pie chart analysis on company market share, 2021(%)
• Johnson & Johnson (US)
• Exhibit Company Overview
• Exhibit Business Segment Overview
• Exhibit Financial Updates
• Exhibit Key Developments
• Boehringer Ingelheim GmbH (Germany)
• Exhibit Company Overview
• Exhibit Business Segment Overview
• Exhibit Financial Updates
• Exhibit Key Developments
• NeuroMetrix, Inc (US)
• Exhibit Company Overview
• Exhibit Business Segment Overview
• Exhibit Financial Updates
• Exhibit Key Developments
• Eli Lilly and Company (US)
• Exhibit Company Overview
• Exhibit Business Segment Overview
• Exhibit Financial Updates
• Exhibit Key Developments
• GlaxoSmithKline plc (UK)
• Exhibit Company Overview
• Exhibit Business Segment Overview
• Exhibit Financial Updates
• Exhibit Key Developments
• Lupin Limited (India)
• Exhibit Company Overview
• Exhibit Business Segment Overview
• Exhibit Financial Updates
• Exhibit Key Developments
• Pfizer Inc (US)
• Exhibit Company Overview
• Exhibit Business Segment Overview
• Exhibit Financial Updates
• Exhibit Key Developments
• Astellas Pharma Inc (Japan)
• Exhibit Company Overview
• Exhibit Business Segment Overview
• Exhibit Financial Updates
• Exhibit Key Developments
• Glenmark Pharmaceuticals Ltd (India)
• Exhibit Company Overview
• Exhibit Business Segment Overview
• Exhibit Financial Updates
• Exhibit Key Developments
• Arbor Pharmaceuticals, LLC (US)
• Exhibit Company Overview
• Exhibit Business Segment Overview
• Exhibit Financial Updates
• Exhibit Key Developments
• Depomed, Inc (US)
• Exhibit Company Overview
• Exhibit Business Segment Overview
• Exhibit Financial Updates
• Exhibit Key Developments